TY  - JOUR

T1  - Pharmacokinetics (PK) and pharmacodynamics (PD) of AMG 162, a fully human monoclonal antibody to Receptor Activator of NF kappa B Ligand (RANKL), following a single subcutaneous dose to patients with cancer-related bone lesions

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2004.22.90140.8106

PY  - 2004/07/15

AU  - Peterson MC

AU  - Martin SW

AU  - Stouch B

AU  - Chen D

AU  - Holloway DL

AU  - Body J-J

AU  - Lipton A

AU  - Coleman R

AU  - Bekker PJ

ED  - 

DO  - DOI: 10.1200/jco.2004.22.90140.8106

PB  - American Society of Clinical Oncology (ASCO)

VL  - 22

IS  - 14_suppl

SP  - 8106

EP  - 8106

Y2  - 2026/10/23

ER  -